(ZNTL) Zentalis Pharmaceuticals - Ratings and Ratios

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company specializing in the discovery and development of small molecule therapeutics for cancer treatment. Its lead candidate, ZN-c3, is a WEE1 kinase inhibitor targeting advanced solid tumors and hematological malignancies. Currently, ZN-c3 is in Phase 2 trials for uterine serous carcinoma and Cyclin E1-driven ovarian cancer, as well as Phase 1/2 trials in combination with PARP inhibitors for platinum-resistant ovarian cancer. Additional studies include combinations with chemotherapy in ovarian, peritoneal, and fallopian tube cancers, osteosarcoma, and pancreatic cancer, as well as a Phase 1/2 trial with encorafenib and cetuximab for mutant metastatic colorectal cancer.

The companys pipeline also features ZN-d5, an oral BCL-2 inhibitor for hematological malignancies, and a BCL-xL heterobifunctional degrader targeting solid and hematological cancers. Zentalis has established strategic collaborations with major players like Pfizer, GlaxoSmithKline, and Dana-Farber, enhancing its research and development capabilities. Founded in 2014 and headquartered in New York, the company has built a robust pipeline focused on addressing unmet needs in oncology.

3-Month Forecast:

Based on the stocks technical profile, ZNTL is currently trading below its 20-day (SMA20: 2.16) and 50-day (SMA50: 2.44) moving averages, indicating bearish momentum. The average true range (ATR: 0.26) suggests moderate volatility. With a last price of 1.87, the stock is 27.9% below its SMA50 and 54.8% below its SMA200 (4.13), signaling potential downside risk in the near term. Support levels may emerge near the stocks historical lows, but the overall trend remains negative unless it regains the SMA20 level.

From a fundamental perspective, Zentalis trades at a price-to-book (P/B) ratio of 0.43, indicating undervaluation relative to its book value. However, the negative return on equity (RoE: -50.60) reflects ongoing operational losses. With a market cap of $143.96M and a price-to-sales (P/S) ratio of 3.55, the stock is sensitive to clinical trial outcomes and partnership developments. Positive data from its pipeline, particularly ZN-c3 trials, could drive upside, but the current financial metrics suggest a high-risk investment profile.